Re:
OptimizeRX Corporation (the “Company”)
Registration
Statement on Form S-1
Filed
November 12, 2008
File
No. 333-455280
|
1.
|
We
remind you of the need to update your interim financial statements. Please
refer to Article 8-08 of Regulation
S-X.
|
2.
|
We
note that you are registering the resale of up to 2,230,000 shares of
common stock that are issuable upon conversion of the Series A preferred
stock. However, on the cover page of the prospectus, you indicate that you
are also registering the resale of shares of common stock issuable upon
exercise of the Series A warrants. Please advise. Also clarify whether the
2,230,000 shares of common stock to which the registration statement
relates includes any shares issuable as dividends on the Series A
preferred stock. If not, please make clear where you discuss the option to
pay dividends in stock in the prospectus that the stock is not included as
part of this offering.
|
3.
|
We
note your statement that the offering price may be the market price
prevailing at the time of sale or a privately negotiated price. We also
note your statement on page 18 that you have proposed a selling price of
$4.05 per share. Please clarify your disclosure. If your selling
shareholder will be selling at a fixed price or price range, please
include that fixed puce or price range on the cover page of your
prospectus. Conforming changes will be required elsewhere in the document,
if your selling shareholder will not be selling at a fixed price or price
range, please advise us of your basis for omitting pricing information.
Item 501(b) (3) of Regulation S-K and Schedule A, paragraph 16, of the
Securities Act of 1933 generally require inclusion of pricing information
in your prospectus.
|
4.
|
Expand
the discussion in this risk factor to include all of the stock issuable as
dividends on the convertible preferred stock and upon exercise of the
warrants issued to the finder in regard to the private placement that
closed in September, 2008.
|
5.
|
Expand
the discussion in this risk factor to quantify the amount of each type of
security outstanding and issuable upon conversion of all outstanding
preferred stock, options and
warrants.
|
6.
|
Ensure
that you have discussed all of the material provisions of the Series A
preferred stock. We note for example, that you do not discuss the
conversion features of the stock. Also ensure that you have defined all
terms used in your discussion. We note that you have not defined the term
“Conversion Price” on page 20.
|
7.
|
Specify
the equity conditions that must be met before you may issue common stock
as dividends on the Series A preferred
stock.
|
8.
|
It
appears that language is missing from the third sentence in the third full
paragraph on page 20. Please
advise.
|
9.
|
In
the third full paragraph on page 22, you refer to a table setting forth
the amount of each payment in connection with the private placement, but
no table appears. Please provide this
information.
|
10.
|
Expand
your discussion to state the extent to which you are currently using funds
in your Operations on a monthly basis, and indicate whether the expected
rate at which capital is used in operations over the 12 month period will
vary from that amount by how much and
why.
|
11.
|
Discuss
your historical sources of liquidity. We note your discussion of sales of
common stock beginning October 2007 through September 2008 discussed on
page II-1.
|
12.
|
Ensure
that you have provided all of the information required by item 403 of
Regulation S-K. We note that Vicis Capital Master Fund is not included on
this table. Please advise.
|
13.
|
Ensure
that you have provided all of the information required by Item 404 of
Regulation S-K. As an example, in regard to the personal loans from the
two private investors, provide the information required by Item 404(a)
(5).
|
14.
|
Ensure
that you have provided all of the information required by Item 702 of
Regulation S-K, including the general effect of any statute under which
any controlling person, officer or director is
indemnified.
|
15.
|
The
Form S-1 must be signed by your Principal Financial Officer and Controller
or Principal Accounting Officer, or persons performing similar functions.
With your next amendment, please provide the appropriate
signatures.
|
·
|
The
Company is responsible for the adequacy and accuracy of the disclosure in
all of its filings;
|
·
|
Any
changes to disclosure in response to the Commission’s comments do not
foreclose the Commission from taking any action with respect to the
filing; and
|
·
|
The
Company may not assert Staff comments as a defense in any proceeding
initiated by the Commission or any person under the federal securities
laws of the United States.
|
Sincerely,
/s/
Dave Harrell
Dave
Harrell
Chief
Executive Officer
|